Non-small-cell lung cancer third-line therapy with gefitinib;Drittlinientherapie mit gefitinib beim nicht-kleinzelligen bronchialkarzinom

Pneumologie

Volumn 59, Issue 5, 2005, Pages 321-327

  Fischer, Jürgen R ^a   Haffner, U ^a   Dietrich, G M ^b   Spahlinger, B ^c   Geiger, D ^a   Lahm, H ^d  

^a Klinik Lowenstein   (Germany)

^b Krankenhaus Bietigheim   (Germany)

^c Praxis Dr Spahlinger ^*  (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; DRUG RESISTANCE; DRUG TARGETING; HUMAN; LUNG NON SMALL CELL CANCER; MOLECULAR BIOLOGY; MOLECULAR TARGETED THERAPY; PRIORITY JOURNAL;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 20344374745     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-830240     Document Type: Article

References (21)

1. Grünwald W, Hidalgo M. Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment. J Natl Cane Inst 2003; 95: 851-867
2. Janmaat ML, Giaccone G. Small-Molecule Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. The Oncologist 2003; 8: 576-586
3. Meert AP, Martin B, Delmotte P et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 2002; 4: 975-981
4. Salomon D, Brandt R, Ciardello F et al. Epidermal Growth Factor-Related Peptides and their Receptors in Human Malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232
5. Cohen MH, Williams GA, Sridhara R et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD 1839; Iressa) tablets. Clin Cancer Res 2004; 15: 1212-1218
6. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase 11 trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2237-2246
7. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomised trial. JAMA 2003; 290: 149-158
8. nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. Proc ASCO 2004; 23: Abst. 7022
9. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1. J Clin Oncol 2004; 22: 777-784
10. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A Phase III Trial: INTACT 2. J Clin Oncol 2004; 22: 785-794
11. Gatzemeier U, Pluzanska A, Szeczesna E et al. Results of a Phase III Trial of Erlotinib (OSI-774) combined with Cisplatin and Gemcitabine Chemotherapy in advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004; 23: Abst. 7010
12. Herbst RS, Prager D, Hermann R et al. TRIBUTE - A phase III trial of erlotinib (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004; 23: Abst. 7011
13. Ciardello F, Caputo R, Bianco R et al. Antitumor Effect and Potentiation of Cytotoxic drugs Activity in Human Cancer Cells by ZD-1839 (Iressa), an Epidermal Growth Factor Receptor-Selective Tyrosine Kinase Inhibitor. Clin Cancer Res 2000; 6: 2053-2063
14. Baselga J. Combining the Anti-EGFR Agent Gefitinib with Chemotherapy in Non-Small-Cell Lung Cancer: How Do We Go From INTACT to Impact? J Clin Oncol 2004; 22: 759-761
15. Moscatello DK, Holgado-Madruga M, Emlet DR et al. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 1998; 273: 200-206
16. Lynch TJ, Bell DW, Sordella R et al. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib. N Engl J Med 2004; 350: 2129-2139
17. Paez JG, Jänne PA, Lee GC et al. EGFR Mutations in Lung Cancer. Correlation with Clinical Response to Gefitinib Therapy. Science 2004; 304: 1497-1500
18. Sordella R, Bell DW, Haber DA et al. Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways. Science 2004; 305: 1163-1167
19. Wittekind C, Wagner G (Hrsg). TNM-Klassifikation maligner Tumoren, 5. Auflage. Berlin Heidelberg: Springer, 1997: 91
20. Miller VA, Kris MG, Shah N et al. Bronchioalveolar Pathologic Subtype and Smoking Predict Sensitivity to Gefitinib in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2004; 22: 1103-1109
21. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci 2004; 101: 13306-13311